Unveiling Albemarle (ALB) Q1 Outlook: Wall Street Estimates for Key Metrics

25.04.25 15:15 Uhr

Werte in diesem Artikel
Aktien

51,23 EUR -0,40 EUR -0,77%

Indizes

1.854,4 PKT -8,4 PKT -0,45%

5.569,1 PKT 8,2 PKT 0,15%

The upcoming report from Albemarle (ALB) is expected to reveal quarterly loss of $0.62 per share, indicating a decline of 338.5% compared to the year-ago period. Analysts forecast revenues of $1.17 billion, representing a decrease of 13.9% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 192.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.In light of this perspective, let's dive into the average estimates of certain Albemarle metrics that are commonly tracked and forecasted by Wall Street analysts.According to the collective judgment of analysts, 'Net Sales- Energy Storage' should come in at $588.57 million. The estimate indicates a year-over-year change of -26.5%.The average prediction of analysts places 'Net Sales- Ketjen' at $243.93 million. The estimate indicates a year-over-year change of +0.1%.The consensus among analysts is that 'Net Sales- Specialties' will reach $329.98 million. The estimate points to a change of +4.4% from the year-ago quarter.Analysts expect 'Adjusted EBITDA- Corporate' to come in at -$9.39 million. Compared to the current estimate, the company reported $26.08 million in the same quarter of the previous year.The combined assessment of analysts suggests that 'Adjusted EBITDA- Ketjen' will likely reach $27.55 million. The estimate is in contrast to the year-ago figure of $21.98 million.The consensus estimate for 'Adjusted EBITDA- Specialties' stands at $55.43 million. Compared to the current estimate, the company reported $45.18 million in the same quarter of the previous year.Analysts predict that the 'Adjusted EBITDA- Energy Storage' will reach $132.93 million. Compared to the present estimate, the company reported $198 million in the same quarter last year.View all Key Company Metrics for Albemarle here>>>Over the past month, shares of Albemarle have returned -22.2% versus the Zacks S&P 500 composite's -4.8% change. Currently, ALB carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Albemarle und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Albemarle

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Albemarle

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Albemarle Corp.

Wer­bung

Analysen zu Albemarle Corp.

DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
10.11.2017Albemarle OutperformRBC Capital Markets
09.11.2017Albemarle NeutralUBS AG
27.10.2017Albemarle OutperformBMO Capital Markets
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
10.11.2017Albemarle OutperformRBC Capital Markets
27.10.2017Albemarle OutperformBMO Capital Markets
08.05.2017Albemarle OutperformRBC Capital Markets
17.03.2017Albemarle OutperformRBC Capital Markets
01.03.2017Albemarle OutperformRBC Capital Markets
DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
09.11.2017Albemarle NeutralUBS AG
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
10.03.2016Albemarle NeutralSeaport Global Securities
03.02.2015Albemarle Market PerformCowen and Company, LLC
DatumRatingAnalyst
16.08.2011Albemarle underperformOppenheimer & Co. Inc.
04.01.2006Update Albemarle Corp.: UnderweightJP Morgan

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Albemarle Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen